|1.||Rustum, Youcef M: 1 article (01/2005)|
|2.||Slocum, Harry K: 1 article (01/2005)|
|3.||Gibbs, John F: 1 article (01/2005)|
|4.||Ikeda, Tomotake: 1 article (01/2002)|
|5.||Samata, Kazunori: 1 article (01/2002)|
|6.||Kuraishi, Aiko: 1 article (01/2002)|
|7.||Kashiwagi, Keiko: 1 article (01/2002)|
|8.||Tanaka, Makoto: 1 article (01/2002)|
|9.||Nakaike, Shiro: 1 article (01/2002)|
|10.||Yamagishi, Takehiro: 1 article (01/2002)|
01/01/1990 - "NC-190, a benzophenazine derivative (N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-carboxamide), was effective against multidrug-resistant human and mouse tumor cells in vitro and in vivo. "
01/01/2005 - "Fifty-five percent (28/51) of fresh human tumors showed sensitivity to 48-h exposure to 10, 30, or 100 microM NC-190. "
07/01/1990 - "Therefore, the antitumor activity of NC-190 in the double grafted tumor system was judged as associated with a sequential immune mechanism in which T cells may play an important role. "
07/01/1990 - "In BALB/c nude mice, NC-190 inhibited slightly the growth of the right tumor but did not that of the left tumor. "
07/01/1990 - "These results suggest that intratumoral administration of NC-190 might induce Lyt-2 positive cytotoxic cells in the spleen and the left, non-treated tumor. "
01/01/1990 - "When vincristine (VCR)-resistant P388 leukemia-bearing mice were treated with an optimal dose of NC-190, four of six mice were cured, whereas treatment of mice with VCR resulted in only a marginal increase in life span. "
01/01/1989 - "In the initial studies with P388 leukemia (i.p.-i.p.), NC-190 led to an increase of greater than 200% in life span (ILS), and 75% of the mice were alive on day 30, when the optimal dose (50 mg/kg, days 1-5) was given. "
|3.||Neoplasm Metastasis (Metastasis)
|4.||Lewis Lung Carcinoma
|5.||Sarcoma (Soft Tissue Sarcoma)
|2.||Type II DNA Topoisomerases (Topoisomerase II)
|3.||procollagen Type I N-terminal peptide (P-I-P)
|6.||Messenger RNA (mRNA)